Posters

3 years experience in using aflibercept in treatment of macular oedema of different aetiology

Poster Details

First Author: G.Zhurgumbayeva KAZAKHSTAN

Co Author(s):    T. Botabekova   Z. Dzhailaubekov   L. Tashtitova                       

Abstract Details



Purpose:

To estimate effectiveness of treatment of the patients with macular oedema of different genesis during 3 years

Setting:

Kazakh Research Institute of Eye Diseases, Almaty, Kazakhstan

Methods:

126 patients with diabetic macular oedema (DMO), 213 patients with Age Related Macular Degeneration (ARMD), 40 patients with retinal central vein occlusion (RCVO), 11 patients with myopic macular retinopathy, 6 patients with macular retinopathy at primary pigmentary degeneration of retina and 2 patients with posttraumatic macular retinopathy have been observed. 10 patients (8 of them with ARMD and 2 with DMO) got intravitreal injections of Lucentis (3 patients), Avastin® (7 patients) in private clinics. Loading injections of aflibercept were done every 4 weeks. Monitoring between injections was not done. In group with DMO 68 eyes (53.9%) had passed laser coagulation of the retina (LCR) in anamnesis. Monotherapy (IVI of aflibercept) was held on 76 (60.3%) eyes and a combined treatment (LKS + IVI of aflibercept) on 50 eyes (39.7%). 46 eyes (36.5%) continued receiving IVIs with interval each 8 weeks and with transferring to regime “Treat-and-Extend” after 6 IVIs. In group with wet ARMD 73 patients (34.3%) continued receiving IVIs by 1 injection in 'Treat-and-Extend' regime. In total 1500 IVIs were done

Results:

In group with DMO maximal corrected vision acuity (MCVA) after 3 injections comprised 0,4±0,08 in average. Thickness of the retina in the centre (TRC) according to the OCT decreased to 281 ±44 мк in average. During 76 weeks and after 3 IVIs, TRC of 46 eyes (36.5%) remained stable, according to the OCT data, and MCVA improved per 1 line. In group with MVD MCVA after 3 injections comprised 0,3±0,09 in average. TRC according to OCT decreased to 270 ±46 мк in average. During 28 weeks and after 3 IVIs MCVA and TRC of 73 patients remained stable according to OCT. In group with RCVO MCVA after 3 injections comprised 0,5±0,07 in average. TRC according to OCT decreased to 282 ±32 мк in average

Conclusions:

1. Aflibercept application allows to reduce TRC in 1.4-2.4 times and increase MCVA in 2-5 times after 3 loading injections. 2. At DMO application of IVVIA in 60.3% of cases is effective as a monotherapy of patients with the passed LCR and in 39.7% of cases in combination with LCR

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy